Products

PhotoClear

Swipe to organize your camera roll. Built with Swift for iOS. - Over 2k downloads -;8% app store conversion rate -;7% download to paid

Website unidentifiedFinance / Investing & Trading

AI Benchmark
Monthly visits
None yet
No traffic data yet
MRR
$110.71
0.0%30d2026-07-30
Entry price
Unknown
Freemium model, plan pricing not identified yet
Creators
Grant Elliott
@grantelltt· 3 followers
Launched
12mo ago
2025-11-30 · Est.

Traffic & revenue

Last 12 months
Monthly visits

No traffic data yet.

Verified monthly revenueRevenue data stopped at 2026-10-11
Events1 marketing move

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on TrustMRRLaunch

    Swipe to organize your camera roll. Built with Swift for iOS. - Over 2k downloads - 7.8% app store conversion rate - 2.7% download to paid

    Nov 30, 2025 · 12mo agoLaunch page

Traffic sources

Traffic breakdown

No traffic channel or country breakdown data for this website yet.

Search

Domain authority —Domain registered Unknown

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Public pricing: Free · In‑App PurchasesRaw source text; structured plans are extracted after website capture.

Pages & changes

Tracked since 2026-07-30

Key pages

Weekly snapshots

No page snapshots yet. Once followed, home and pricing pages are captured weekly.

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

What is PhotoClear and what platforms does it support?
PhotoClear is catalogued under Investing & Trading: Swipe to organize your camera roll. Built with Swift for iOS. - Over 2k downloads -;8% app store conversion rate -;7% download to paid. Supported platforms: Web.
What is PhotoClear's publicly disclosed revenue?
TrustMRR records verified MRR of $110.71 observed on 2026-07-30.Source

Related products in this category

Finance / Investing & Trading

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.